Indicated for the treatment of: Multiple Myeloma (MM): Often used for maintenance therapy post-transplant or for dose reduction due to toxicity. Myelodysplastic Syndromes (MDS): For patients with deletion 5q cytogenetic abnormality and renal issues. Mantle Cell Lymphoma.

Dosage and administration

Strength: 5 mg capsule. Dosing for Renal Impairment: Moderate impairment (CrCl 30-60 mL/min): Often adjusted to 10 mg daily. Severe impairment (CrCl < 30 mL/min, not on dialysis): 15 mg every 48 hours (using combinations) or specifically titrated. End Stage Renal Disease (on Dialysis): 5 mg once daily. On dialysis days, administer the dose AFTER dialysis. ⚠️ Do NOT break or open capsules. Teratogenic hazard.

Even at 5 mg, significant risks exist: Venous Thromboembolism: Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Anticoagulant prophylaxis is required. Hematologic: Neutropenia and Thrombocytopenia (requires regular CBC monitoring). Constitutional: Fatigue, asthenia, constipation, and rash.

Lenalid 5 — Lenalidomide 5 mg, 30 product-page.units_short, Natco

100% original product

Active ingredient

Lenalidomide

Manufacturer

Natco

Dosage 5 mg

Dosage form Capsules

Capsules per pack 30

Lenalid 5 — Lenalidomide 5 mg

Name: Lenalid 5
Brand: Natco
SKU: PROD-25
Price: 2907 UAH
Availability: InStock

2907₴ ~~3471₴~~ -16%

Lenalid 5 mg is the lowest strength capsule of the immunomodulatory drug Lenalidomide.

Manufacturer: Natco Pharma (India). Generic version of Revlimid.

Specific Use Case:

This 5 mg dosage is crucial for renal dose adjustments. It is designed for patients with compromised kidney function (Renal Impairment) or for those who experience severe adverse reactions (like neutropenia/thrombocytopenia) on higher doses.

✅ Benefit: Allows continuous therapy for fragile or elderly patients.

Indicated for the treatment of:

Multiple Myeloma (MM): Often used for maintenance therapy post-transplant or for dose reduction due to toxicity.
Myelodysplastic Syndromes (MDS): For patients with deletion 5q cytogenetic abnormality and renal issues.
Mantle Cell Lymphoma.

Strength: 5 mg capsule.

Dosing for Renal Impairment:

Moderate impairment (CrCl 30-60 mL/min): Often adjusted to 10 mg daily.
Severe impairment (CrCl < 30 mL/min, not on dialysis): 15 mg every 48 hours (using combinations) or specifically titrated.
End Stage Renal Disease (on Dialysis): 5 mg once daily. On dialysis days, administer the dose AFTER dialysis.

⚠️ Do NOT break or open capsules. Teratogenic hazard.

🚫 PREGNANCY WARNING (Black Box): Must not be used by pregnant women. Causes severe birth defects or fetal death.

Other Contraindications:

Hypersensitivity to lenalidomide.
Breastfeeding.

Even at 5 mg, significant risks exist:

Venous Thromboembolism: Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Anticoagulant prophylaxis is required.
Hematologic: Neutropenia and Thrombocytopenia (requires regular CBC monitoring).
Constitutional: Fatigue, asthenia, constipation, and rash.